HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $404,059 | +0.0% | 11,199 | 0.0% | 0.23% | -12.5% |
| Q2 2023 | $403,948 | -5.6% | 11,199 | 0.0% | 0.26% | +6.9% |
| Q1 2023 | $427,690 | -32.9% | 11,199 | 0.0% | 0.25% | -51.4% |
| Q4 2022 | $637,223 | -99.9% | 11,199 | 0.0% | 0.51% | +34.2% |
| Q3 2022 | $442,808,000 | -10.1% | 11,199 | 0.0% | 0.38% | -4.3% |
| Q2 2022 | $492,756,000 | +110136.2% | 11,199 | 0.0% | 0.40% | +55.7% |
| Q1 2022 | $447,000 | -99.9% | 11,199 | +25.8% | 0.26% | +83.5% |
| Q4 2021 | $357,828,000 | -1.2% | 8,899 | 0.0% | 0.14% | +21.9% |
| Q3 2021 | $362,011,000 | -25.4% | 8,899 | -16.7% | 0.11% | -19.1% |
| Q2 2021 | $485,115,000 | +8.9% | 10,683 | 0.0% | 0.14% | +11.9% |
| Q1 2021 | $445,374,000 | +48.1% | 10,683 | +51.7% | 0.13% | +68.0% |
| Q4 2020 | $300,764,000 | – | 7,042 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |